COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

被引：0
|
作者：
Guan, X. [1 ]
Li, H. [1 ]
Chen, Q. [2 ]
Hao, C. [3 ]
Li, J. [4 ]
Wang, Y. [5 ]
Zhang, J. [4 ]
Xu, H. [1 ]
Liu, C. [6 ]
Chu, Y. [7 ]
Ma, A. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
[2] Guangdong Tradit Chinese Med Hosp, Guangzhou, Guangdong, Peoples R China
[3] Tianjin Med Univ Canc Hosp, Tianjin, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Shandong Canc Hosp, Jinan, Shandong, Peoples R China
[6] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
[7] Shanghai Roche Pharmaceut Ltd, Beijing 11, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CC4
引用
收藏
页码：S405 / S406
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
    Garrison, Louis P., Jr.
    Babigumira, Joseph
    Tournier, Clement
    Goertz, Hans-Peter
    Lubinga, Solomon J.
    Perez, Edith A.
    [J]. VALUE IN HEALTH, 2019, 22 (04) : 408 - 415
  • [2] COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA
    Li, H.
    Guan, X.
    Chen, Q.
    Hao, C.
    Li, J.
    Wang, Y.
    Zhang, J.
    Li, K.
    Liu, C.
    Chu, Y.
    Ma, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [3] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States (vol 22, pg 408, 2019)
    Minckwitz, Von
    [J]. VALUE IN HEALTH, 2019, 22 (07) : 843 - 843
  • [4] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
  • [5] Cost-effectiveness of adjuvant chemotherapy plus trastuzumab (T) in HER2-positive breast cancer
    Liberato, N. L.
    Marchetti, M.
    Barosi, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI6 - XI6
  • [6] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    [J]. CANCER, 2007, 110 (03) : 489 - 498
  • [7] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [8] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    [J]. ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [9] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
    Guan, X.
    Li, H. C.
    Xia, Y.
    Yang, Q.
    Ma, A. X.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
  • [10] BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
    Dang, Chau
    Ewer, Michael S.
    Delaloge, Suzette
    Ferrero, Jean-Marc
    Colomer, Ramon
    de la Cruz-Merino, Luis
    Werner, Theresa L.
    Dadswell, Katherine
    Verrill, Mark
    Eiger, Daniel
    Sarkar, Sriparna
    de Haas, Sanne Lysbet
    Restuccia, Eleonora
    Swain, Sandra M.
    [J]. CANCERS, 2022, 14 (11)
12345